Nature of the Case and Issue(s) Presented: Merck owned U.S. Patent No. 6,670,340 (“the ‘’340 patent”), which issued on Dec. 30, 2003, and claimed a class of 6-mercaptocyclodextrin derivatives, ...
The Federal Circuit heard oral argument in Auribundo's appeal of the district court's decision in favor of plaintiff Merck, in a case captioned In re Sugammadex (alternatively, Aurobindo v. Merck ...
WALB Investigates Team received the motion filed Oct. 29, 2025, Merck Co. is asking a Georgia court to dismiss a lawsuit tied ...
In January 2025, Wockhardt announced that ZAYNICH demonstrated unprecedented efficacy in a global, pivotal Phase III study ...
NEW YORK CITY, NY / ACCESS Newswire / December 2, 2025 / Merck Sharp & Dohme LLC ("Merck") recently suffered a data breach that compromised the sensitive personal data of individuals. This data breach ...
Merck Sharp & Dohme LLC has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis ...
Attorneys from Gibbons have entered appearances for Merck Sharp & Dohme in a pending patent infringement lawsuit. The complaint, filed Sept. 5 in New Jersey District Court by Skiermont Derby and Sills ...
Merck Sharp & Dohme LLC has patented new 5,6 saturated bicyclic heterocyles acting as NLRP3 inflammasome inhibitors potentially useful for the treatment of atherosclerosis, metabolic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback